Study: NCT00577096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A home-based individualized exercise program that incorporated aerobic and strength resistance training.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplantation
Description: Standard PBSCT for multiple myeloma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusion
Description: RBC Transfusion was administered as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Fifty percent of the participants received 400 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Transfusion
Description: Platelet transfusions were administered as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Therapy II
Description: Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: RBC Transfusion was administered as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Fifty percent of participants received 400 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: Platelet transfusions were administered as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma